Your browser is no longer supported. Please, upgrade your browser.
Genprex, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own17.46% Shs Outstand39.67M Perf Week5.69%
Market Cap210.78M Forward P/E7.43 EPS next Y0.60 Insider Trans0.18% Shs Float33.74M Perf Month-8.79%
Income-17.90M PEG- EPS next Q- Inst Own16.30% Short Float10.35% Perf Quarter14.95%
Sales- P/S- EPS this Y24.00% Inst Trans1.85% Short Ratio2.30 Perf Half Y20.22%
Book/sh0.78 P/B5.72 EPS next Y116.30% ROA-68.90% Target Price- Perf Year106.48%
Cash/sh0.58 P/C7.72 EPS next 5Y- ROE-70.10% 52W Range1.95 - 7.72 Perf YTD7.47%
Dividend- P/FCF- EPS past 5Y-50.20% ROI- 52W High-42.23% Beta-
Dividend %- Quick Ratio61.50 Sales past 5Y- Gross Margin- 52W Low128.72% ATR0.42
Employees12 Current Ratio68.10 Sales Q/Q- Oper. Margin- RSI (14)46.31 Volatility9.79% 8.15%
OptionableYes Debt/Eq0.01 EPS Q/Q5.90% Profit Margin- Rel Volume0.76 Prev Close4.87
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.52M Price4.46
Recom2.00 SMA20-4.74% SMA50-15.33% SMA20011.50% Volume1,171,593 Change-8.42%
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
Apr-05-21 08:30AM  
Mar-30-21 08:30AM  
Mar-24-21 08:30AM  
Mar-01-21 08:30AM  
Feb-09-21 08:30AM  
Feb-08-21 03:30PM  
Feb-04-21 08:30AM  
Feb-01-21 01:30PM  
Jan-28-21 08:35AM  
Jan-27-21 08:30AM  
Jan-21-21 08:30AM  
Jan-14-21 08:30AM  
Jan-13-21 09:00AM  
Dec-24-20 01:02PM  
Dec-23-20 12:40PM  
Dec-22-20 01:15PM  
Dec-17-20 08:47AM  
Dec-08-20 08:16AM  
Dec-03-20 08:17AM  
Nov-30-20 02:05PM  
Nov-24-20 09:30AM  
Nov-11-20 08:16AM  
Nov-10-20 08:17AM  
Oct-30-20 08:17AM  
Oct-29-20 08:16AM  
Oct-26-20 08:16AM  
Oct-07-20 08:17AM  
Oct-06-20 08:16AM  
Sep-21-20 08:17AM  
Sep-09-20 04:25PM  
Sep-02-20 05:36PM  
Aug-26-20 08:17AM  
Aug-05-20 03:34PM  
Jul-31-20 08:17AM  
Jul-30-20 08:16AM  
Jul-21-20 12:58PM  
Jun-29-20 08:16AM  
Jun-25-20 08:17AM  
Jun-24-20 08:16AM  
Jun-16-20 08:17AM  
Jun-09-20 08:17AM  
Jun-08-20 08:17AM  
May-28-20 08:17AM  
May-05-20 01:00PM  
May-04-20 08:17AM  
Apr-21-20 08:17AM  
Mar-24-20 08:17AM  
Mar-23-20 08:17AM  
Mar-05-20 08:05AM  
Mar-04-20 08:00AM  
Mar-03-20 08:17AM  
Feb-21-20 04:15PM  
Feb-20-20 10:22AM  
Feb-19-20 09:23AM  
Feb-11-20 08:17AM  
Feb-06-20 08:17AM  
Feb-05-20 09:00AM  
Feb-03-20 08:17AM  
Jan-29-20 08:18AM  
Jan-28-20 08:00AM  
Jan-24-20 07:00AM  
Jan-23-20 09:00AM  
Jan-22-20 10:54AM  
Jan-21-20 08:00AM  
Jan-06-20 08:00AM  
Nov-20-19 11:15AM  
Nov-19-19 08:00AM  
Nov-04-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 08:00AM  
Oct-07-19 08:00AM  
Sep-26-19 08:30AM  
Sep-25-19 08:30AM  
Sep-18-19 08:00AM  
Sep-11-19 08:00AM  
Sep-07-19 04:35PM  
Sep-06-19 08:30AM  
Sep-04-19 01:43PM  
Aug-23-19 08:30AM  
Aug-22-19 08:30AM  
Aug-21-19 03:31PM  
Aug-13-19 08:00AM  
Aug-06-19 08:00AM  
Jul-31-19 08:30AM  
Jul-09-19 01:58PM  
Jul-01-19 08:30AM  
May-31-19 08:30AM  
May-30-19 08:35AM  
May-21-19 08:30AM  
Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LONGNECKER BRENT MDirectorApr 05Buy4.1515,00062,25015,000Apr 07 04:41 PM